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Background: In addition to the frequently reported pain complaints, performance-based 
cognitive capabilities in patients with chronic fatigue syndrome (CFS) with and without 
comorbid fibromyalgia (FM) are significantly worse than those of healthy controls. In various 
chronic pain populations, cognitive impairments are known to be related to pain severity. 
However, to the best of our knowledge, the association between cognitive performance and 
experimental pain measurements has never been examined in CFS patients.
Objectives: This study aimed to examine the association between cognitive performance and 
self-reported as well as experimental pain measurements in CFS patients with and without FM.
Study Design: Observational study. 
Setting: The present study took place at the Vrije Universiteit Brussel and the University of 
Antwerp.
Methods: Forty-eight (18 CFS-only and 30 CFS+FM) patients and 30 healthy controls 
were studied. Participants first completed 3 performance-based cognitive tests designed to 
assess selective and sustained attention, cognitive inhibition, and working memory capacity. 
Seven days later, experimental pain measurements (pressure pain thresholds [PPT], temporal 
summation [TS], and conditioned pain modulation [CPM]) took place and participants were 
asked to fill out 3 questionnaires to assess self-reported pain, fatigue, and depressive symptoms.
Results: In the CFS+FM group, the capacity of pain inhibition was significantly associated 
with cognitive inhibition. Self-reported pain was significantly associated with simple reaction 
time in CFS-only patients. The CFS+FM but not the CFS-only group showed a significantly 
lower PPT and enhanced TS compared with controls.
Limitations: The cross-sectional nature of this study does not allow for inferences of 
causation.
Conclusions: The results underline disease heterogeneity in CFS by indicating that a measure 
of endogenous pain inhibition might be a significant predictor of cognitive functioning in 
CFS patients with FM, while self-reported pain appears more appropriate to predict cognitive 
functioning in CFS patients without FM.
Key words: Chronic fatigue syndrome, cognitive function, cognitive inhibition, chronic pain, 
fibromyalgia, pain inhibition, pain-related cognitive impairment, working memory
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cluster with other symptoms and pathophysiological 
features of the disorder. Furthermore, since we believe 
that disease heterogeneity and the effect of comorbidi-
ties such as FM might play a significant role, this study 
aimed to examine the association between cognitive 
performance and self-reported as well as experimental 
pain measurements in CFS patients with comorbid FM.
Methods
Study Design and Setting
This blinded case-control study took place at the 
Pain in Motion research labs in Antwerp and Brussels. 
The study was approved by the ethics committees of 
the University Hospital Brussels/Vrije Universiteit Brus-
sel and the University Hospital Antwerp, and written 
informed consent was obtained from all participants 
prior to commencement of the study.
Participants and Assessments
Patients with CFS were recruited from a private 
practice for internal medicine, by calls during patient 
information sessions, and advertisements placed in 
the newsletter of a local patient support group. Writ-
ten confirmation of a CFS diagnosis as defined by the 
United States Centers for Disease Control and Preven-
tion (CDC) 1994 criteria for CFS (1) was required from 
each participant’s physician before study participation. 
After inclusion in the study, patients with CFS were 
split up into a group of patients with and without 
comorbid FM (CFS+FM and CFS, respectively). The co-
morbid presence of FM was identified according to the 
American College of Rheumatology (ACR) 2010 criteria 
for fibromyalgia (25). Furthermore, a third group that 
consisted of healthy inactive control persons was in-
cluded. Healthy [pain-free and without any (chronic) 
disease] inactive control persons were relatives, friends, 
or acquaintances of researchers, students, university 
personnel, or patients participating in the study. “In-
active” was defined as working in an occupation that 
did not require moderate to intense physical labor and 
performing a maximum of 3 hours of moderate physical 
activity/week. Moderate physical activity is defined as 
activity demanding at least the threefold of the energy 
spent passively (26).
Each study participant had to be Dutch speak-
ing and aged between 18 and 65 years. To preclude 
confounding factors, participants could not suffer 
from intellectual disabilities and women could not be 
pregnant or until one year postnatal. Furthermore, 
Chronic fatigue syndrome (CFS) is a debilitating and complex disorder characterized by profound fatigue for 6 or more consecutive 
months that is not improved by bed rest and that may be 
worsened by physical or mental activity. In the majority 
of CFS patients, this chronic fatigue is accompanied 
by widespread and persistent pain as well (1). Chronic 
widespread musculoskeletal pain is the hallmark 
symptom of fibromyalgia (FM), and furthermore it is 
known that patients with CFS and patients with FM 
share many other symptoms and clinical features such 
as fatigue, sleep disturbances, cognitive dysfunction, 
and mood disturbances (2-5). A growing body of 
scientific literature designates central sensitisation (CS) 
as a common pathophysiological mechanism in these 
overlapping conditions (6-9). 
CS has been defined as “an amplification of neural 
signalling within the central nervous system that elicits 
pain hypersensitivity” (10). Clinically it manifests as an 
increased response to various peripheral stimuli (e.g., 
pressure, light, sound, cold, and heat among others) 
inducing hyperalgesia and allodynia (8,11).
In addition to the pain, both CFS and FM patients 
frequently complain of decreased cognitive capabili-
ties (12). Accordingly, we recently demonstrated that 
performance-based cognitive capabilities are signifi-
cantly worse both in CFS patients with and without FM 
compared with healthy controls (13). Indeed, an over-
lap exists in components of the pain neuromatrix and 
brain regions involved in cognitive processing (e.g., 
anterior cingulate cortex, insular cortex, periaqueduc-
tal gray) (14). Together with the demonstrated changes 
in neuroplasticity [e.g., gray matter volume reduction 
(15-17)] and dysregultated neurochemistry [e.g., de-
creased levels of brain-derived neurotrophic factor 
(18), increased levels of gamma-aminobutric acid (19), 
increased levels of pro-inflammatory cytokines (20)], 
these pain-induced changes in resource utilization may 
(in part) explain (pain-related) cognitive impairment in 
chronic pain patients.
Some previous studies indicated that, in patients 
with FM, cognitive performance is inversely related to 
self-reported pain (21,22), while other authors demon-
strated an absence of this relationship in FM patients 
(15,23) and in female CFS patients (24). However, to 
the best of our knowledge the association between 
cognitive performance and experimental pain measure-
ments and established measures of CS has never been 
examined in CFS patients. Examing this association can 
give us more insight in how cognitive dysfunctions can 
www.painphysicianjournal.com  E843
Associations Between Cognitive Performance and Pain in Chronic Fatigue Syndrome
all participants, if applicable, were asked to stop anti-
depressive, anti-epileptic, and opioid pain medication 
2 weeks prior to study participation and were asked 
not to undertake physical exertion, and to refrain from 
taking analgesics and consuming caffeine, alcohol. or 
nicotine on the days of the assessments.
The study consisted of 2 assessment sessions sepa-
rated by 7 days. All assessments were performed by the 
same researchers who were blinded to whether partici-
pants were patients or controls. On the first day, after 
signing the informed consent form, collecting personal 
characteristics (age, gender, height, weight, disease 
duration, FM criteria, and occupational status) and 
checking for the presence of possible confounders, all 
participants completed 3 performance-based cognitive 
tests on a computer. Seven days later, experimental pain 
measurements took place and participants were asked 
to fill out 3 questionnaires [the Medical Outcomes Study 
36-Item Short-Form Health Survey (SF-36), the Checklist 
Individual Strength (CIS), and the Beck Depression In-
ventory for Primary Care (BDI-PC)]. Finally, at the end 
of the second assessment session, the success of assessor 
blinding was examined by asking whether the assessor 
thought the participant belonged to the patient (CFS or 
CFS+FM) or control group.
Cognitive Tests
To investigate cognitive function the Stroop task, 
psychomotor vigilance task (PVT), and operation span 
(OSPAN) task with concomitant mathematical pro-
cessing were used. All 3 tests were conducted on the 
same computer and in the same order (1. Stroop task, 
2. PVT, 3. OSPAN) by every participant. To ensure stan-
dardization of the procedure, each test began with the 
presentation of written instructions for that particular 
test. Short breaks (± 5 minutes) between each test were 
allowed. Completion of the entire test battery took 
about 50 minutes. Each of the 3 tests have been used 
and described in detail in 2 of our previous studies in 
female CFS patients (24,27).
The Stroop task (28) was used to assess selective at-
tention, cognitive inhibition, and choice reaction time 
(RT). In this test, different stimuli (= words or XXX) ap-
peared in different colors (yellow, green, red, or blue) in 
the middle of the computer screen. The meaning of the 
stimulus is the task-irrelevant dimension and the color 
in which the stimulus is presented is the task-relevant 
dimension. Accordingly, participants were instructed 
to respond to the presented ink color in which stimuli 
were written, by pressing the corresponding color-key 
on the keyboard as quickly and as accurately as pos-
sible. The presented stimuli could be classified under 
2 different conditions, namely “incongruent” (word 
and color are different [e.g., the word red displayed in 
green]) and “no word” [XXX presented in one color]). 
Mean response RT and accuracy were stored for each 
condition. In order to quantify cognitive inhibition, the 
RT of the no word condition was subtracted from the 
RT of the incongruent condition. Thus, an interference 
score (Stroop INT) is provided which can be seen as an 
indicator of the inhibition subcomponent of executive 
functioning. Deficits in cognitive inhibition should re-
sult in an increased Stroop INT.
The PVT (29) was used to assess sustained atten-
tion (or vigilance) and simple RT. Participants were 
instructed to respond to a visual stimulus (red spot on 
black background) that appeared in the middle of the 
screen at random inter-stimulus intervals (2 – 10 s). They 
were required to press the mouse button as quickly as 
possible whenever they perceived the appearance of 
the stimulus on the screen. If the participant did not 
respond within 500 ms, the trial was stored as a lapse. 
The PVT ran for a total time of 10 minutes. The mean 
RT of correct responses (< 500 ms) and the number of 
lapses were stored.
Working memory capacity was assessed using the 
OSPAN task with concomitant mathematical processing 
as described by Conway and Engle (30). The task began 
with a practice block (divided into 3 sections). First, par-
ticipants got the chance to practice the simple letter 
span. They saw letters appear on the screen one at a 
time. After having seen the whole letter span they had 
to recall these letters in the same order they saw them. 
Next, participants practiced the mathematical portion 
of the OSPAN task. They first saw a mathematical op-
eration appear on the screen (e.g., [7*3] – 3 = ?). Then, 
a number (e.g., 18) was presented on the screen and 
participants were instructed to indicate whether the 
number was the correct solution or not by clicking on 
“True” or “False.” The final practice session consisted of 
performing both the letter recall and the mathematical 
operations together. Participants first had to solve the 
mathematical operation and only then saw the letter 
to be recalled. The dual-task design with the math-
ematical processing was used in order to keep the task-
relevant information (letter span) active and accessible 
in memory during the execution of complex cognitive 
tasks (mathematical operations). After the completion 
of the 3 practice sessions, the program automatically 
proceeded to the experimental block which was the 
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same as the final practice session (mathematical opera-
tions + letter recall). The experimental block consisted 
of 3 sets of each set size (ranging from 3 – 7). Thus, a 
total of 75 letters and 75 mathematical problems were 
presented. At the end of the experiment, the “OSPAN 
total score” was registered and used for further data 
analyses. This score indicates the number of letters 
recalled in the correct position (regardless of whether 
the whole letter set was correct) and is a measure of 
working memory capacity.
Experimental Pain Measurements
Pressure Pain Thresholds
Pressure pain thresholds (PPTs) were measured at 
the middle of the right trapezius belly (PPT shoulder) 
and at the dorsal surface of the right hand middle 
finger midway between the first and second distal 
joint (PPT finger) with an analogue Fisher algometer 
(Force Dial, Wagner Instruments, Greenwich CT, USA) 
(31,32). Participants’ PPTs were determined by gradu-
ally increasing the pressure provided by the algometer 
(at a rate of 1 kg/s) until the point the sensation first 
became painful (participants were instructed to say 
“stop” at this point). This was performed 2 times (30 
seconds apart) at the shoulder and at the finger in or-
der to calculate the mean PPT for every site. Pressure 
algometry has been found to be efficient and reliable 
in the exploration of pathophysiological mechanisms 
involved in pain (33,34).
Endogenous Pain Facilitation: Temporal 
Summation
Temporal summation (TS) was examined 2 minutes 
after the final PPT was taken at each site (finger and 
shoulder). Participants were given 10 pulses to the pre-
viously determined mean PPT intensity and this pressure 
was maintained for one second before being released. 
Pressure was increased at a rate of approximately 2 kg/s 
for each pulse and pulses were presented with an in-
terstimulus interval of one second. After the first, fifth, 
and thenth pulse, the participant was asked to verbally 
rate his/her pain on a Visual Analogue Scale (VAS) rang-
ing from 0 (= no pain) to 10 (= worst possible pain). The 
outcome measure for TS is the difference between the 
tenth and the first VAS score (31,32).
Endogenous Pain Inhibition: Conditioned Pain 
Modulation
To assess conditioned pain modulation (CPM), 
experimental pain measures (TS) were taken while an 
occlusion cuff was inflated to a painful intensity and 
maintained at that level on the opposing (left) arm (as 
a heterotopic noxious conditioning stimulus). The cuff 
was inflated at approximately 20 mmHg/s until the 
point the sensation first became painful (participants 
were instructed to say “stop” at this point). Next, they 
adapted for 30 seconds to the stimulus and subsequent-
ly rated their pain on a VAS. Cuff inflation was then in-
creased or decreased until the participant indicated the 
pain level was equal to 3 on 10 on the VAS. The left arm 
was then rested on a table and CPM was assessed by 
replicating the TS assessment as described above. The 
outcome measure for CPM is the difference between 
the first VAS score before cuff inflation and the first 
VAS score during cuff inflation (31,32).
Self-Reported Pain
The SF-36 is a widely used generic health status 
survey that consists of 36 questions which all together 
measure 8 health concepts: (1) physical functioning, 
(2) role limitations because of physical health prob-
lems, (3) bodily pain, (4) general health perceptions, 
(5) vitality (energy/fatigue), (6) social functioning, (7) 
role limitations because of emotional problems, and 
(8) general mental health (21). For this study we were 
only interested in the bodily pain concept of the SF-36. 
Consequently, only the bodily pain score of the SF-36 
was used in the analyses. The raw score was coded and 
transformed into a scale from 0 to 100, with a higher 
score representing less bodily pain (35). The SF-36 has 
been documented to have reliability and validity in a 
wide variety of patient populations (36,37). Further-
more, it appears to be one of the most frequently used 
patient-reported measures in the assessment of adults 
with CFS (38).
Self-Reported Fatigue 
The CIS (39) consists of 20 items which altogether 
measure 4 dimensions of fatigue, including (1) subjec-
tive fatigue severity, (2) reduced concentration, (3) 
reduced motivation, and (4) reduced physical activity 
level. Respondents have to indicate, on a 7-point Likert 
scale, the degree to which each item was true for them 
in the 2 weeks preceding the assessment. Higher scores 
represent a higher level of fatigue and lower levels of 
concentration, motivation, and physical activity. For this 
study only the subjective fatigue severity dimension of 
the CIS was used in the analyses (as a covariate in the 
regression analyses). The CIS has good discriminative 
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validity, and its 4 dimensions have excellent consistency 
(Cronbach’s α varying from 0.83 to 0.92) (39,40).
Depression
The BDI-PC (41) was used for the assessment of de-
pressive symptoms. It is a 7-item self-report instrument. 
Each of these 7 items contains 4 statements and respon-
dents are asked to indicate the statement that best 
suits their feelings for the past 2 weeks including today. 
Within each item statements are rated on a 4-point 
scale ranging from 0 to 3. The BDI-PC is scored by sum-
ming all of the highest ratings for each item. Hence, 
the  maximum total score is 21. Items are symptoms of 
sadness, pessimism, past failure, loss of pleasure, self-
dislike, self-criticalness, and suicidal thoughts or wishes. 
The BDI-PC has high internal-consistency (Cronbach’s α 
of 0.85) (41).
Statistical Analysis
Data analyses were performed using IBM SPSS 
Statistics 22.0 for Windows (IBM Corp., Armonk, NY, 
USA). Normality of the variables was tested using the 
Kolmogorov-Smirnov goodness of fit test and through 
visual inspection of the histograms and distribution 
graphs. Comparability of the groups was studied with 
a Pearson Chi-Square test for gender distribution and 
occupational status and with a one-way independent 
analysis of variance (ANOVA) for age, body mass, 
height, body mass index, and disease duration.
Experimental pain, self-reported pain, fatigue, 
and depression measurements were compared among 
the groups with a one-way independent ANOVA for 
variables that were normally distributed. When a sig-
nificant main effect was found, Bonferroni post hoc 
comparisons were performed to identify the significant 
differences among the 3 groups. Variables lacking nor-
mal distribution were compared with a non-parametric 
independent-samples Kruskal-Wallis test. Post hoc 
paired comparisons were performed when a main ef-
fect was found.
To determine the association between pain mea-
surements and cognitive performance, correlation 
analyses (Pearson’s and Spearman’s) were performed. 
Because of  the exploratory nature of this study and 
to minimize the risk of type II errors, no correction for 
multiple comparisons was done when calculating the 
statistical significance of the correlations. For all cor-
relation analyses, only the pain outcomes that revealed 
the strongest association with performance on cogni-
tive tests (based on P-values as well as on correlation co-
efficients) were considered for further regression analy-
ses. Hence, the outcome of the correlation analyses was 
used only for identifying the appropriate variables for 
the regression analysis.
Simple linear regression analyses were performed 
to determine whether measurements of pain (experi-
mental and self-reported) could be significant predic-
tors of cognitive performance in patients with CFS and 
CFS+FM. Because age (14), fatigue severity (42), and 
depressive symptoms (43) may significantly influence 
cognitive function as well as pain measurements, the 
analyses were also performed with these variables 
separately entered as additional predictor variables 
(covariates).
For all comparisons (except for the correlation 
analyses), a 2-sided P < 0.05 was considered statistically 
significant. Data are reported as mean (SD) and median 
(Q1; Q3) within the text and the tables.
Power calculations were performed with the 
program G*Power 3.1.5 (Kiel, Germany) (44). Because 
in this report the same study samples (and hence the 
same sample sizes) were used as in our previous report 
on the association between upper limb muscle recovery 
and cognitive performance (13), no additional a priori 
sample size calculation was performed. Hence, in order 
to improve the interpretation of the results a post hoc 
power analysis for the linear regression analyses was 
performed when associations were not significant. This 
is discussed in the discussion section.
Results
Group Characteristics 
Forty-eight patients with CFS were included in this 
study. These patients were split up into a group of 30 
CFS patients with FM (CFS+FM) and a group of 18 CFS 
patients without FM (CFS). This implies that 62.5% of 
the included CFS patients also met the ACR 2010 criteria 
for FM. Furthermore, 30 healthy inactive controls were 
included. Table 1 shows the demographic data of the 3 
study samples. The groups were comparable for gender 
distribution, age, body weight, and body mass index 
(P > 0.05), but not for body height [F2,75 = 4.69, P = 
0.012] and occupational status [χ2(6) = 17.74, P = 0.007]. 
Disease duration was not significantly different (P = 1.0) 
between the CFS+FM and CFS group.
Cognitive Performance
For the results on cognitive performance, we refer 
the reader to our second report (13). Summarized, 
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these results showed that the CFS+FM group showed 
significantly decreased RTs (simple and choice), cogni-
tive inhibition, and selective and sustained attention in 
comparison with the control group (P < 0.05). Although 
the CFS group also showed worse results on cognitive 
tests compared with the control group, these differ-
ences were only significant for simple RT (P < 0.05).
Pain Measurements
Outcomes of the experimental and self-reported 
pain measurements are presented in Table 2. For the 
experimental pain measurements, the one-way inde-
pendent ANOVAs indicated significant main effects for 
the PPTs measured at the shoulder (F2, 75 = 3.94, P = 
0.026) and TS at the finger (F2, 75 = 4.17, P = 0.019). 
Subsequent post hoc analyses revealed a significantly 
lower PPT (P = 0.036) and enhanced TS (P = 0.017) in the 
CFS+FM group compared with the control group, while 
there were no significant differences between both pa-
tient groups nor between the CFS and control group (P 
> 0.05). PPTs at the finger, TS at the shoulder, and CPM 
(finger and shoulder) were comparable between the 3 
groups (P > 0.05).
Self-reported pain, measured with the bodily pain 
concept of the SF-36, was significantly different among 
the 3 groups (F2, 75 = 41.97, P < 0.001). More specifi-
cally, both patient groups showed significantly lower 
scores (representing more bodily pain) compared with 
the controls (both P > 0.001). Additionally, the CFS+FM 
group scored significantly lower than the CFS group (P 
= 0.004).
Fatigue and Depression
Both patient groups reported significantly more 
fatigue (CIS) relative to controls (H2 = 49.68, P < 0.001; 
post hoc paired comparisons indicated P < 0.001 in both 
patient groups vs. controls). A significant main effect 
was also found for the scores on the BDI-PC (H2 = 12.86, 
P = 0.002). Post hoc paired comparisons indicated a 
significantly higher BDI-PC score (representing more 
depressive symptoms) in the CFS+FM group compared 
with the control group (P = 0.001). No other significant 
differences were found (P > 0.05).
Association between Pain Measurements and 
Cognitive Performance
Correlation analyses
In the CFS+FM group, CPM measured at the finger 
was significantly related to OSPAN total score (r = 0.55, 
P = 0.002) and Stroop interference (r = -0.41, P = 0.023). 
No significant correlations were found between self-
reported bodily pain and cognitive performance in this 
group (P > 0.05).
In the CFS group, the correlation analyses revealed 
significant negative correlations between CPM mea-
sured at the finger and OSPAN total score (r = -0.52, P = 
0.026), and between PPT at the finger and the number 
of lapses on the PVT (r = -0.53, P = 0.025). Furthermore, 
significant negative associations were found between 
self-reported bodily pain and PVT RT (r = -0.68, P = 
0.002), Stroop RT of the no-word condition (r = -0.48, 
P = 0.043) and Stroop interference (r = -0.59, P = 0.01).
Table 1. Demographic data of  the study samples.
Values are mean (SD) or number (%).
CFS = patients with chronic fatigue syndrome; CFS+FM = patients with chronic fatigue syndrome + fibromyalgia; CON = healthy inactive controls.
a Statistical analyses were performed using a one-way independent analysis of variance.
b Statistical analyses were performed using a Pearson’s Chi-Square test.
c Significant difference between CFS+FM and CON (P < 0.01).
d Significant difference between both CFS+FM and CFS versus CON (P < 0.001).
CFS (n = 18) CFS+FM (n = 30) CON (n = 30)
Age (years)a 40.6 (12.5) 40.2 (10.7) 37.3 (14.5)
Women, n (%)b 17 (94.4) 29 (97.7) 25 (83.3)
Body Mass (kg)a 70.6 (15.3) 68.4 (12.7) 70.6 (15.7)
Height (cm)a 167.9 (5.8) 166.0 (5.2)c 170.6 (6.5)
Body Mass Indexa 25.1 (5.3) 24.8 (4.3) 24.2 (4.7)
Disease Duration (months)a 154.1 (186.5) 135.0 (103.5) 0.0 (± 0.0)d
Occupational status, n (%)b
13 inactive (72.2)
2 part-time (11.1)
1 full-time (5.6)
2 students (11.1)
18 inactive (60)
5 part-time (16.7)
3 full-time (10)
4 students (13.3)
8 inactive (26.7)
2 part-time (6.7)
11 full-time (36.7)
9 students (30)
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No significant correlations between pain measure-
ments (experimental and self-reported) and cognitive 
performance were found in the control group (P > 0.05).
Regression Analyses
Based on the outcome of the correlation analyses, 
CPM measured at the finger and the bodily pain score 
of the SF-36 were considered, as experimental and self-
reported pain measurement respectively, for further 
regression analyses. To determine whether pain-related 
measurements could be predictors of cognitive perfor-
mance in patients with CFS and CFS with comorbid FM, 
simple linear regression analyses were performed with 
“CPM finger” (as experimental pain measurement) and 
“SF-36 bodily pain” (as self-reported pain measure-
ment) entered as predictor variables. Table 3 presents 
the results of the regression analyses in both patient 
groups (CFS and CFS+FM) without covariates (age, fa-
tigue, and depression). The analyses revealed that, in 
patients with CFS+FM, CPM is a significant predictor for 
a higher OSPAN total score (= better working memory 
capacity) (P = 0.002) and lower Stroop INT score (= better 
cognitive inhibition) (P = 0.007). These results remained 
significant when age (R2 = 0.34, β = 0.51, P = 0.004 and 
R2 = 0.24, β = -0.45, P = 0.014, respectively), fatigue (R2 
= 0.31, β = 0.57, P = 0.002 and R2 = 0.23, β = -0.48, P = 
0.011, respectively), and depression (R2 = 0.30, β = 0.56, 
P = 0.002 and R2 = 0.27, β = -0.43, P = 0.016, respectively) 
were included as separate covariates in the analyses. 
Self-reported pain (SF-36 bodily pain) seemed neither 
a significant predictor for cognitive performance (P > 
0.05) in patients with CFS+FM without covariates nor 
after controlling for age, fatigue, and depression (P > 
0.05). 
In the CFS-only group, CPM is a significant predic-
tor for a worse OSPAN total score (= worse working 
memory capacity) (P = 0.026). When age was entered 
as a covariate, the significant negative association 
between CPM and OSPAN total score remained (R2 = 
0.32, β = -0.51, P = 0.03). However, including fatigue 
as a covariate resulted in CPM no longer being a sig-
nificant predictor for OSPAN total score (R2 = 0.44, β = 
-0.40, P = 0.69) and, in contrast, becoming a significant 
predictor for a higher Stroop INT score (= worse cogni-
tive inhibition) (R2 = 0.28, β = 0.54, P = 0.032). Enter-
ing depression as a covariate resulted in a significant 
association between both CPM and OSPAN total score 
(R2 = 0.29, β = -0.52, P = 0.03) and CPM and Stroop INT 
score (R2 = 0.33, β = 0.46, P = 0.047). Self-reported pain 
(SF-36 bodily pain) seemed to be a significant predictor 
for PVT RT (P = 0.002) in the CFS-only group. This result 
remained significant when age (R2 = 0.50, β = -0.72, P 
= 0.001), fatigue (R2 = 0.47, β = -0.68, P = 0.003), and 
depression (R2 = 0.54, β = -0.80, P = 0.001) were included 
as separate covariates.
Success of Assessor Blinding
With regard to the CFS patients (CFS+FM and CFS-
only), in 62.5% of the cases (30 out of 48) the assessor’s 
guess about disease status was correct. In the control 
CFS (n = 18) CFS+FM (n = 30) CON (n = 30)
PPT finger (kg/cm2)a 7.4 (5.7) 5.7 (2) 6.9 (2.3)
PPT shoulder (kg/cm2)a 3.8 (3.2) 2.5 (1.5)c 3.9 (1.7)
TS fingera 1.7 (1.4) 2.5 (1.5)c 1.4 (1.6)
TS shouldera 1.3 (1.7) 2.2 (2.2) 1.3 (1.4)
CPM fingerb 0.0 (-0.3; 0.3) 0.0 (-1.0; 1.0) 0.0 (-0.3; 0.0)
CPM shoulderb 0.0 (-1.0; 0.3) 0.0 (-0.1; 1.0) 0.0 (-1.0; 1.0)
SF-36
Bodily paina 59.1 (24.3) 
e 39.9 (19.6) 85 (14.6)d
CIS
Subjective fatigueb 53.0 (49.0; 54.0) 50.5 (45.8; 55.0) 20.5 (12.8; 32.8)
d
BDI-PCb 2.0 (0.8; 4.0) 3.0 (1.0; 7.0)c 0.5 (0.0; 2.0)
Values are mean (SD) or median (Q1; Q3).
CFS = patients with chronic fatigue syndrome; CFS+FM = patients with chronic fatigue syndrome + fibromyalgia; CON = healthy inactive controls.
a Statistical analyses were performed using a one-way independent analysis of variance.
b Statistical analyses were performed using an independent-samples Kruskal Wallis test.
c Significant difference between CFS+FM and CON (P < 0.05).
d Significant difference between both CFS+FM and CFS versus CON (P < 0.001).
e Significant difference between CFS+FM and CFS (P < 0.005).
Table 2. Comparison of  pain and self-reported measurements among the study samples.
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group the assessor assumed correctly in 90% of the 
cases (27 out of 30).
discussion
This study was the first to investigate the associa-
tion between cognitive performance and experimental 
pain measurements and measures of CS in patients with 
CFS. In addition, to extend previous investigations, CFS 
patients were subgrouped into CFS-only and CFS+FM 
Dependent 
variable
Predictor 
variable
B SE (B) β
P - 
value
t R2 B
SE 
(B) β
P - 
value
t R2
CFS+FM (n = 30) CFS (n = 18)
Predicting cognitive performance on an experimental pain measurement (CPM)
Stroop
RT IC
Constant 1208.88 112.4 1398.76 190.37
CPM finger -42.69 77.72 -0.10 0.671 -0.43 0.01 -0.75 180.6 -0.00 0.989 -0.14 0.00
Stroop
RT NWC
Constant 1103.67 72.28 994.87 60.51
CPM finger -116.28 49.97 -0.40 0.929 -0.09 0.00 109.81 57.41 0.43 0.799 -0.26 0.00
Stroop 
INT
Constant 211.49 63.36 150.77 62.09
CPM finger -126.73 43.81 -0.48 0.007 -2.89 0.23 122.50 58.90 0.46 0.054 2.08 0.21
PVT RT
Constant 343.41 8.83 320.97 8.63
CPM finger -8.96 6.11 -0.27 0.154 -1.47 0.07 -1.10 8.19 0.03 0.899 0.13 0.00
PVT
Lapses
Constant 16.50 3.41 9.41 2.86
CPM finger -3.56 2.35 -0.28 0.693 -0.40 0.01 3.31 2.72 0.29 0.777 -0.29 0.01
OSPAN Constant 50.43 2.49 54.52 2.22
Total Score CPM finger 5.98 1.72 0.55 0.002 3.48 0.30 -5.15 2.11 -0.52 0.026 -2.44 0.27
Predicting cognitive performance on self-reported pain (SF-36 bodily pain)
Stroop RT 
IC
Constant 972.60 253.76 1847.24 496.29
SF-36 BP 6.08 5.72 0.20 0.226 1.24 0.05 -7.60 7.81 -0.24 0.251 -1.19 0.08
Stroop RT 
NWC
Constant 1180.39 180.41 1250.63 167.59
SF-36 BP -1.48 4.07 -0.07 0.266 1.14 0.04 -4.12 2.64 -0.36 0.232 -1.24 0.09
Stroop INT
Constant 386.92 162.09 396.10 177.10
SF-36 BP -3.92 3.66 -0.20 0.293 -1.07 0.04 -3.92 2.79 -0.33 0.178 -1.41 0.11
PVT RT
Constant 345.51 21.00 379.70 16.96
SF-36 BP -0.02 0.47 -0.01 0.968 -0.04 0.00 -0.99 0.27 -0.68 0.002 -3.72 0.46
PVT Lapses
Constant 20.49 8.08 26.03 6.73
SF-36 BP -0.09 0.18 -0.09 0.528 0.62 0.01 -0.28 0.11 -0.55 0.434 -0.80 0.04
OSPAN Constant 50.74 6.81 54.98 6.98
Total Score SF-36 BP -0.03 0.15 -0.04 0.846 -0.20 0.00 -0.02 0.11 -0.04 0.875 -0.16 0.00
Table 3. Results of  simple linear regression analyses predicting cognitive performance on experimental and self-reported pain 
measures in patients with CFS+FM and patients with CFS.
CFS = patients with chronic fatigue syndrome; CFS+FM = patients with chronic fatigue syndrome + fibromyalgia; CPM finger = conditioned pain 
modulation measured at the finger; SF-36 BP = bodily pain concept of the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36); 
RT IC = reaction time incongruent condition; RT NWC = reaction time no word condition; PVT = psychomotor vigilance task; OSPAN = opera-
tion span.
Significant P-values are printed in bold.
patients to determine the influence of comorbid 
FM on CFS patients’ self-reported and experimental 
pain outcomes and their associations with cognitive 
performance.
The results of this study demonstrate that the 
presence of comorbid FM certainly has an impact on 
outcomes when studying patients with CFS. More spe-
cifically, we found CFS+FM patients being more severely 
affected, by demonstrating hyperalgesia, enhanced 
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tween self-reported pain and simple RT, while the post 
hoc power analyses revealed low power (≤ 66%) for de-
tecting significant associations between self-reported 
pain and measures of selective attention, choice RT and 
cognitive inhibition. Thus, here as well false negative 
results, probably because of the small sample size, can-
not be excluded.
In summary, regarding the associations between 
cognitive performance and pain measurements, this 
study revealed that CPM might be a significant predictor 
of cognitive performance in CFS patients with comorbid 
FM, while self-reported pain might be a predictor of 
cognitive performance in CFS patients without FM. CPM 
efficiency represents an important brain-orchestrated 
inhibitory mechanism of pain processing (45). A higher 
CPM value reflects a more efficient pain inhibitory re-
sponse. Subsequently, in the CFS+FM group, significant 
associations with CPM were found with cognitive tasks 
demanding high levels of inhibitory control (i.e., work-
ing memory and cognitive inhibition). These findings 
show that in CFS+FM patients inhibition of environmen-
tal and internal distractions and the capacity of pain 
inhibition go hand in hand. We therefore hypothesize 
that malfunctioning of descending inhibitory pathways 
(e.g., serotonergic and noradrenergic descending path-
ways) precludes optimal cognitive function in these 
patients. On the other hand, the activation of overlap-
ping brain regions leading to competition between 
pain and cognition for processing resources in the 
brain, may explain worse inhibition of environmental 
and internal distractions in the presence of better pain 
inhibitory capacity and vice versa in CFS-only patients. 
These findings, together with the more pronounced 
cognitive problems in CFS+FM patients compared to 
those without FM, suggest a different – however,  not 
necessarily mutually exclusive – neurobiological  basis 
of pain-related cognitive impairment in both groups 
(13). To better understand the mechanisms underlying 
these cognitive dysfunctions, further research with di-
rect monitoring of brain activity (e.g., using functional 
magnetic resonance imaging) is warranted. 
This study suggests that endogenous pain inhibi-
tion and self-reported pain are clinically important 
measures in CFS patients with and without comorbid 
FM, respectively. Indeed, these measures are not only 
important tools for the evaluation of CS in these pa-
tients, but reduced values could also be an indication to 
clinicians to monitor their patients’ cognitive function. 
Hence, therapy should not merely target the patients’ 
return to physical but also to cognitive tasks. 
endogenous pain facilitation, and significantly more 
depressive symptoms compared with healthy controls, 
while this was not the case in the CFS-only group. Fur-
thermore, the results indicate that a measure of endog-
enous pain inhibition might be a significant predictor 
of cognitive performance in CFS patients with comorbid 
FM, while a self-reported pain measure appears more 
appropriate to predict cognitive performance in CFS 
patients without FM.
Patients with CFS and comorbid FM were more 
disabled than CFS patients without FM, as evidenced 
by their lower PPTs, more enhanced TS, more self-
reported pain and depressive symptoms compared to 
the CFS-only group. However, these differences be-
tween both patient groups only reached significance 
for self-reported pain. Nevertheless, the CFS+FM group 
showed hyperalgesia and enhanced pain facilitation. 
This was evidenced by a significantly lower PPT at the 
shoulder and enhanced TS at the finger compared with 
healthy controls, while CFS-only patients on the other 
hand showed no hyperalgesia and exhibited normal 
endogenous pain modulation (both pain facilitation 
and inhibition). These findings support our earlier sug-
gestion (13), namely, that reducing the heterogeneity 
of the disorder in future research could be important to 
better understand and uncover mechanisms regarding 
the nature of divers impairments in patients with CFS.
Our results furthermore showed that CPM mea-
sured at the finger is able to predict working memory 
capacity and cognitive inhibition in CFS patients with 
FM. Associations with other cognitive variables were 
not significant. Nevertheless, the post hoc power analy-
ses revealed only moderate power (≤ 71%) for detect-
ing associations between CPM and measures of selec-
tive attention and simple RT. This means that a false 
negative result, probably as a result of the small sample 
size, cannot be excluded in these cases. Conversely, 
the power was sufficiently high (≥ 91%) to detect as-
sociations between CPM and measures of choice RT and 
sustained attention, meaning that these results were 
true negative. A low power (≤ 58%) was also found 
in 4 out of 6 regression analyses of self-reported pain 
and cognitive performance. This possibly explains the 
absence of significant associations between cognitive 
performance and self-reported pain in this group.
In CFS-only patients, despite the sufficiently high 
power and apart from one significant negative asso-
ciation with working memory capacity, we did not find 
significant associations between CPM and cognitive 
performance. A significant association was found be-
Pain Physician: September/October 2015; 18:E841-E852
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In addition, it would be most valuable for future 
research to examine these associations in other chronic 
pain conditions, particularly in highly heterogeneous 
patient groups such as complex regional pain syndrome 
among others.
The findings of this study should be interpreted 
minding its methodological strengths and weaknesses. 
First, it should be mentioned that the groups were 
rather small for the regression analyses. Since the pow-
er of the non-significant associations was oftentimes 
rather low, this could possibly explain the absence of 
significance in some of these associations (i.e., possible 
type II errors in the associations between CPM and 
measures of selective attention and simple RT in the 
CFS+FM group and between self-reported pain and 
cognitive performance in both groups). Second, the 
cross-sectional nature of this study does not allow for 
inferences of causation. Additionally, given the absence 
of previous data regarding the association between 
cognitive performance and pain measurements in these 
subgroups, an exploratory approach was used to test 
several hypotheses. Although we accounted adequate-
ly for possible type I errors in the statistical analyses, 
the latter entails that findings must be considered 
cautiously. Future studies should try to account for the 
aforementioned limitations by increasing their sample 
sizes. Furthermore, the findings of this study yet again 
confirm the prevalent heterogeneity within people 
suffering from CFS and consequently, the importance 
of taking this into account in future research. Lastly, 
the generalizability of our results might be reduced 
because only Belgian people were studied here. There-
fore, care should be taken when applying the results 
to foreign patient populations such the US population, 
among others.
The most important strength of this study is that 
our control group was matched to both patient groups 
for age, gender, and body mass index. Furthermore, 
both CFS groups were matched for disease duration as 
well. Additionally, healthy controls had to be inactive 
because it is known that CFS patients, in general, have 
a more sedentary lifestyle (46). This way, observed dif-
ferences could not be due to a higher activity level of 
the control group. Another important strength of this 
study is that we anticipated sources of bias like preg-
nancy; use of medication, caffeine, alcohol, and nico-
tine; and execution of physical exertion on the days of 
the assessments. Moreover, we accounted statistically 
for age, fatigue severity, and depressive symptoms and 
we reduced the heterogeneity of the disease as well 
by including CFS patients according to the same strict 
diagnostic criteria and in addition dividing this group 
based on FM comorbidity. A final study strength worth 
mentioning is that we attempted to blind the assessor 
regarding participants’ disease status. However, this 
was only successful in 37.5% of the patients and in 10% 
of the controls. 
conclusion
In conclusion, this study shows that associations 
between cognitive performance and pain measure-
ments are different in CFS patients with and without 
FM. Although larger confirmatory studies are needed, 
these study findings suggest that better endogenous 
pain inhibition could predict better mental health in 
patients with CFS and comorbid FM, while less self-
reported pain could predict better mental health in 
CFS patients without FM. Reducing the heterogeneity 
of CFS in future research is important to better under-
stand and uncover the underlying mechanisms of divers 
impairments, including cognitive impairments, in these 
patients. This will ultimately lead to improvements of 
guided therapy.
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